Nanobiotix Reports Final Preclinical Safety Data: Its 'NBTXR3' Nanoparticles Are Designed to Be Safe and Effective Treatment for Radiosensitive and Radioresistant Tumors
7/9/2009 9:23:10 AM
PARIS--(BUSINESS WIRE)--Nanobiotix, an emerging nanomedicine company, announced today that preclinical follow-up data regarding long-term toxicity evaluation suggests that its patented NBTXR3 nanoparticles are designed to be a safe and effective treatment for radiosensitive and radioresistant tumors. The preclinical studies were performed at NAMSA Biomatech. NAMSA is registered with the CDER and CBER divisions of the FDA.
comments powered by